This week INFARMED organised the fifth meeting under the scope of the Portuguese Presidency of the Council of the European Union. Over the course of two days the session brought together about 50 participants, members of the Clinical Trials Facilitation Group (CTFG).
Paricipants debated and shared their experiences on clinical trials relating to vaccines and COVID/19 therapies, with the goal of perfecting the validation process.
The meeting also served to assess the status of a set of technical and legal issues, namely new future regulations, the update of the ongoing projects such as, the Clinical Trials Information System (CTIS), in addition to assessing the groups future initiatives.
INFARMED’s Vice-President, António Faria-Vaz, opened the session highlighting the importance of CTFG during the challenges of last year’s pandemic, whilst also emphasizing the relevance of the goals of the group cooperation between EU Member States in the sphere of Clinical Trials.
The European Clinical Trials Facilitation Group (CTFG) was created in 2004 with the aim of coordinating the implementation of Directive 2001 / 20 / EC, for all member states of the European Union. It acts as a forum for discussing principles and procedures applicable across the EU, with the aim of promoting harmonisation of clinical trial evaluation decision and procedures at EU level.
The meeting is part of the set of 20 meetings of the several Committees and Working Groups that INFARMED will be holding during the next months of the Presidency.Saber mais